Abstract
Early postpartum hemorrhage remains a significant cause of maternal morbidity and mortality. Postpartum hemorrhage is most commonly due to uterine atony and often responds to medical treatments such as administration of uterotonic drugs, alone or in combination with uterine massage or bimanual compression. As the incidence of cesarean section continues to rise, the problem of placenta previa and accreta is likely to become more common. For first-line management of postpartum hemorrhage adequate blood and fluid replacement is mandatory. In recent years new therapeutic measures to control the bleeding have gained attention. Although, these newer therapies focus on avoiding the need for emergency hysterectomy and preservation of reproductive function, reports of subsequent pregnancies are still scarce. Established management options are shortly reviewed and novel medical and surgical treatments are more extensively discussed.
Keywords: postpartum hemorrhage, atony, recombinant activated factor VII, tranexamic acid
Current Pharmaceutical Design
Title: Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Volume: 11 Issue: 6
Author(s): F. W. Bouwmeester, A. C. Bolte and H. P. van Geijn
Affiliation:
Keywords: postpartum hemorrhage, atony, recombinant activated factor VII, tranexamic acid
Abstract: Early postpartum hemorrhage remains a significant cause of maternal morbidity and mortality. Postpartum hemorrhage is most commonly due to uterine atony and often responds to medical treatments such as administration of uterotonic drugs, alone or in combination with uterine massage or bimanual compression. As the incidence of cesarean section continues to rise, the problem of placenta previa and accreta is likely to become more common. For first-line management of postpartum hemorrhage adequate blood and fluid replacement is mandatory. In recent years new therapeutic measures to control the bleeding have gained attention. Although, these newer therapies focus on avoiding the need for emergency hysterectomy and preservation of reproductive function, reports of subsequent pregnancies are still scarce. Established management options are shortly reviewed and novel medical and surgical treatments are more extensively discussed.
Export Options
About this article
Cite this article as:
Bouwmeester W. F., Bolte C. A. and van Geijn P. H., Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage, Current Pharmaceutical Design 2005; 11 (6) . https://dx.doi.org/10.2174/1381612053381882
DOI https://dx.doi.org/10.2174/1381612053381882 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Engineering Three-Dimensional Cardiac Microtissues for Potential Drug Screening Applications
Current Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Substance P and its Inhibition in Ocular Inflammation
Current Drug Targets <i>Chlamydia pneumoniae</i> and<i> Mycoplasma pneumoniae</i> as Two Emerging Risk Factors in Atherosclerosis: Meta-Analysis Study and Systematic Review
Infectious Disorders - Drug Targets Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets The Impact of Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants
Current Pharmaceutical Design Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets The Mediterranean Diet: A Combination of Beneficial Elements for Cardiovascular Disease
Current Nutrition & Food Science Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science 5-Adenosine Monophosphate-Activated Protein Kinase and the Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets